KROS: Kapitalisasi marang bathi resik kanthi nimbang wutah kerostx.com

Simbol lan logo merek kerostx.com (KROS)

Keros Therapeutics (KROS) minimizes capital risks by developing diversified biopharmaceuticals for the treatment of muscle and blood pathologies. The P/E ratio relative to medium-term growth illustrates the business valuation trend, where the 0.00 level reflects the current magnitude. However, the high cost of clinical phases and reliance on academic alliances create certain challenges, despite patent protection and FDA support.

Keros Therapeutics (KROS) - Pangali PEG saka 04.07.2022 nganti 16.11.2026

Keros Therapeutics, Inc. (KROS) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:Keros Pharma - KROS
Produk sing diprodhuksi kerostx.com

The business model of Keros Therapeutics (KROS) is attractive due to the humanitarian status of its developments, which completely neutralizes geopolitical risks and sanction barriers. This indicator compares the current P/E ratio with expected earnings growth to determine the asset's fair value relative to its expansion. An analysis of the PEG momentum ratio reveals a fundamental undervaluation of the company when business growth rates significantly outpace the market value of the shares.

Perusahaan pesaing